Table 3 Gender wise distribution of Genotype frequency and genetic model analysis for CDKN2B rs3217992 among POAG and PACG cases with respect to control subjects
Males with POAG and PACG versus control male subjects | ||||||||
|---|---|---|---|---|---|---|---|---|
Genotype | POAG n = 200 (%) | Control n = 227 (%) | p value | OR(CI) | PACG n = 51 (%) | Control n = 227 (%) | p value | OR(CI) |
CC | 74(37) | 66(29.07) | Ref | Â | 19(37.25) | 66(29.07) | Ref | Â |
CT | 92(46) | 113(49.77) | 0.145 | 0.72(0.47–1.11) | 27(52.94) | 113(49.77) | 0.58 | 0.83(0.42–1.60) |
TT | 34(17) | 48(21.14) | 0.101 | 0.63(0.36–1.09) | 5(9.80) | 48(21.14) | 0.058a | 0.36(0.12–1.03) |
Genetic models | ||||||||
Dominant model | 126/74 | 161/66 | 0.082 | 0.69(0.46–1.04) | 32/19 | 161/66 | 0.253 | 0.69(0.36–1.30) |
Recessive model | 92/108 | 113/114 | 0.435 | 0.85(0.58–1.25) | 27/24 | 113/114 | 0.683 | 1.13(0.61–2.08) |
Additive model | 160/240 | 209/245 | 0.075 | 0.78 (0.59–1.02) | 37/65 | 212/244 | 0.061 | 0.65 (0.42–1.02) |
Females with POAG and PACG versus control female subjects | ||||||||
|---|---|---|---|---|---|---|---|---|
Genotype | POAG n = 113 (%) | Control n = 217 (%) | p value | OR(CI) | PACG n = 94 (%) | Control n = 217 (%) | p value | OR(CI) |
CC | 45(39.82) | 72(33.17) | Ref | Â | 39(41.48) | 72(33.17) | Ref | Â |
CT | 47(41.59) | 101(46.54) | 0.255 | 0.74(0.44–1.23) | 43(45.74) | 101(46.54) | 0.371 | 0.78(0.46–1.33) |
TT | 21(18.58) | 44(20.27) | 0.408 | 0.76(0.46–1.20) | 12(12.76) | 44(20.27) | 0.072 | 0.50(0.23–1.06) |
Genetic models | ||||||||
Dominant model | 68/45 | 145/72 | 0.231 | 0.75(0.46–1.20) | 55/39 | 145/72 | 0.161 | 0.70(0.42–1.15) |
Recessive model | 47/66 | 101/116 | 0.391 | 0.81(0.51–1.21) | 43/51 | 101/116 | 0.896 | 0.96(0.59–1.57) |
Additive model | 89/137 | 189/245 | 0.303 | 0.84(0.60–1.16) | 67/121 | 189/245 | 0.066 | 0.71(0.50–1.02) |